IN2012DN03348A - - Google Patents

Download PDF

Info

Publication number: IN2012DN03348A
Authority: IN; India
Prior art keywords: monoclonal antibodies; methods; progastrin; compositions; present disclosure
Prior art date: 2009-10-16

Application number

Other languages

English (en)

Inventor

Pannequin Julie

Boudier Laure

Joubert Dominique

Hollande Frederic

Original Assignee

Biorealites

Inst Nat Sante Rech Med

Centre Nat Rech Scient

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-16

Filing date

2010-10-15

Publication date

2015-10-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN03348(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-10-15 Application filed by Biorealites, Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Biorealites

2015-10-23 Publication of IN2012DN03348A publication Critical patent/IN2012DN03348A/en

Links

101800000285 Big gastrin Proteins 0.000 abstract 6
RZIMNEGTIDYAGZ-HNSJZBNRSA-N pro-gastrin Chemical compound N([C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(=O)[C@@H]1CCC(=O)N1 RZIMNEGTIDYAGZ-HNSJZBNRSA-N 0.000 abstract 6
238000000034 method Methods 0.000 abstract 5
206010009944 Colon cancer Diseases 0.000 abstract 3
208000001333 Colorectal Neoplasms Diseases 0.000 abstract 3
239000000203 mixture Substances 0.000 abstract 3
239000012634 fragment Substances 0.000 abstract 2
238000011319 anticancer therapy Methods 0.000 abstract 1
238000001514 detection method Methods 0.000 abstract 1
238000012544 monitoring process Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Hospice & Palliative Care (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Oncology (AREA)
Biophysics (AREA)
Food Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

IN3348DEN2012 2009-10-16 2010-10-15 IN2012DN03348A (ro)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25262509P	2009-10-16	2009-10-16
PCT/EP2010/006329 WO2011045080A2 (en)	2009-10-16	2010-10-15	Monoclonal antibodies to progastrin and their uses

Publications (1)

Publication Number	Publication Date
IN2012DN03348A true IN2012DN03348A (ro)	2015-10-23

Family

ID=43086711

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN3348DEN2012 IN2012DN03348A (ro)	2009-10-16	2010-10-15

Country Status (43)

Country	Link
US (7)	US9611320B2 (ro)
EP (2)	EP2488551B1 (ro)
JP (3)	JP5985987B2 (ro)
KR (2)	KR101640520B1 (ro)
CN (2)	CN102791735B (ro)
AP (1)	AP2012006262A0 (ro)
AR (1)	AR078659A1 (ro)
AU (1)	AU2010306119A1 (ro)
BR (1)	BR112012008818B1 (ro)
CA (1)	CA2777691C (ro)
CL (1)	CL2012000914A1 (ro)
CR (1)	CR20120184A (ro)
CU (1)	CU24196B1 (ro)
CY (1)	CY1120913T1 (ro)
DK (1)	DK2488551T3 (ro)
EA (2)	EA029271B1 (ro)
EC (1)	ECSP12011796A (ro)
ES (2)	ES2690943T3 (ro)
GE (1)	GEP201706604B (ro)
GT (1)	GT201200114A (ro)
HK (1)	HK1178183A1 (ro)
HN (1)	HN2012000708A (ro)
HR (1)	HRP20181645T1 (ro)
IL (2)	IL219019B (ro)
IN (1)	IN2012DN03348A (ro)
LT (1)	LT2488551T (ro)
MA (1)	MA33747B1 (ro)
MX (1)	MX351635B (ro)
NI (1)	NI201200054A (ro)
NZ (2)	NZ701709A (ro)
PE (1)	PE20121649A1 (ro)
PH (1)	PH12012500711B1 (ro)
PL (2)	PL2488551T3 (ro)
PT (1)	PT2488551T (ro)
RS (1)	RS57966B1 (ro)
SG (1)	SG10201704933PA (ro)
SI (1)	SI2488551T1 (ro)
SM (1)	SMT201800628T1 (ro)
TN (1)	TN2012000159A1 (ro)
TW (1)	TWI537002B (ro)
UA (1)	UA106771C2 (ro)
WO (1)	WO2011045080A2 (ro)
ZA (1)	ZA201202642B (ro)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8136651B2 (en) *	2007-12-14	2012-03-20	The Procter & Gamble Company	Method and apparatus for orienting articles
WO2008076454A1 (en)	2006-12-19	2008-06-26	The Board Of Regents Of The University Of Texas System	Immunogenic compositions comprising progastrin and uses thereof
IN2012DN03348A (ro) *	2009-10-16	2015-10-23	Biorealites
US9487582B2 (en) *	2010-01-08	2016-11-08	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Methods for treating pancreatic cancer
US8900817B2 (en)	2010-01-08	2014-12-02	Les Laboratories Servier	Progastrin and liver pathologies
AU2011231978B2 (en) *	2010-03-24	2014-12-18	Centre National De La Recherche Scientifique (Cnrs)	Prophylaxis of colorectal and gastrointestinal cancer
CN103261224B (zh) *	2010-07-26	2015-10-07	瑟维尔实验室	用于肝癌治疗的方法和组合物
US8785603B2 (en)	2011-05-20	2014-07-22	Siemens Healthcare Diagnostics Inc.	Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
EP2715364A1 (en)	2011-06-01	2014-04-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for predicting the risk of developing a colonic neoplasia
US9803017B2 (en)	2013-07-05	2017-10-31	University Of Washington Through Its Center For Commercialization	Soluble MIC neutralizing monoclonal antibody for treating cancer
US10023651B2 (en)	2014-04-18	2018-07-17	The Research Foundation For The State University Of New York	Humanized anti-TF-antigen antibodies
BR112016024214B8 (pt) *	2014-04-18	2023-12-26	Univ New York State Res Found	Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal
WO2016066671A1 (en)	2014-10-29	2016-05-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for treating resistant cancers using progastrin inhibitors
AU2016324021A1 (en) *	2015-09-15	2018-04-12	The Scripps Research Institute	Antibodies for generating anti-inflammatory macrophage and related uses
MA43550A (fr) *	2015-12-31	2018-11-07	Syncerus S A R L	Compositions et procédés d'évaluation du risque d'apparition d'un cancer
JP6909795B2 (ja) *	2015-12-31	2021-07-28	プロガストリン、エ、カンセル、エス、アーエル、エルＰｒｏｇａｓｔｒｉｎｅＥｔＣａｎｃｅｒｓＳ．ＡＲ．Ｌ．	胃癌の検出および治療のための組成物および方法
KR102428254B1 (ko) *	2015-12-31	2022-08-03	프로가스트린 에 캔서스 에스.에이 알.엘.	난소암의 검출 및 치료를 위한 조성물 및 방법
WO2018178364A1 (en) *	2017-03-30	2018-10-04	Progastrine Et Cancers S.À R.L.	Compositions and methods for treating lung cancer
EP3601347B1 (en) *	2017-03-30	2021-11-03	Progastrine et Cancers S.à r.l.	Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
CA3084687C (en) *	2017-12-05	2024-01-02	Progastrine Et Cancers S.A R.L.	Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
CN112004560A (zh)	2017-12-08	2020-11-27	Ecs生物识别系统有限公司	癌症诊断中的放射性标记的前胃液素
TW201940881A (zh)	2018-01-26	2019-10-16	瑞士商Ｅｃｓ前胃泌激素公司	在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
CN112368579B (zh) *	2018-02-27	2024-05-03	Ecs前胃泌素股份有限公司	作为生物标记物的前胃泌素用于免疫疗法
TWI793238B (zh) *	2018-12-27	2023-02-21	偉喬生醫股份有限公司	體外檢測生物樣品之胃源性蛋白的方法及套組
CN112062846A (zh) *	2020-04-27	2020-12-11	杭州博茵生物技术有限公司	一种g-17单克隆抗体及其应用
CN115785273B (zh) *	2021-09-10	2023-10-31	东莞市朋志生物科技有限公司	一种抗胃蛋白酶原i的抗体及其应用
CN116143920A (zh) *	2022-12-30	2023-05-23	南京岚煜生物科技有限公司	胃泌素17的单克隆抗体及其细胞株的制备方法和应用
US20250059271A1 (en) *	2023-08-16	2025-02-20	Barrelman Biosciences Llc	Monoclonal antibodies against veterinary progastrin-like molecules and their uses
CN117567611B (zh) *	2023-11-22	2024-05-14	艾维可生物科技有限公司	抗成熟型胃泌素17的单克隆抗体及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
ATE356869T1 (de)	1990-01-12	2007-04-15	Amgen Fremont Inc	Bildung von xenogenen antikörpern
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
MX9204374A (es)	1991-07-25	1993-03-01	Idec Pharma Corp	Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
CA2124967C (en)	1991-12-17	2008-04-08	Nils Lonberg	Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
US8158128B2 (en) *	2004-09-22	2012-04-17	Cancer Advances, Inc.	Monoclonal antibodies to progastrin
CA2652768A1 (en) *	2006-05-22	2007-11-29	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Inhibitors of progastrin-induced repression of icat for treating and/or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells andcells in which the beta-catenin/tcf-4-mediated transcriptional pathway is constitutively active
WO2008076454A1 (en) *	2006-12-19	2008-06-26	The Board Of Regents Of The University Of Texas System	Immunogenic compositions comprising progastrin and uses thereof
EP2337795A2 (en) *	2008-10-01	2011-06-29	Dako Denmark A/S	Mhc multimers in cancer vaccines and immune monitoring
IN2012DN03348A (ro) *	2009-10-16	2015-10-23	Biorealites
AU2011231978B2 (en) *	2010-03-24	2014-12-18	Centre National De La Recherche Scientifique (Cnrs)	Prophylaxis of colorectal and gastrointestinal cancer

2010
- 2010-10-15 IN IN3348DEN2012 patent/IN2012DN03348A/en unknown
- 2010-10-15 AU AU2010306119A patent/AU2010306119A1/en not_active Abandoned
- 2010-10-15 PT PT10768878T patent/PT2488551T/pt unknown
- 2010-10-15 PL PL10768878T patent/PL2488551T3/pl unknown
- 2010-10-15 EP EP10768878.0A patent/EP2488551B1/en active Active
- 2010-10-15 PE PE2012000434A patent/PE20121649A1/es active IP Right Grant
- 2010-10-15 JP JP2012533531A patent/JP5985987B2/ja active Active
- 2010-10-15 MX MX2012004400A patent/MX351635B/es active IP Right Grant
- 2010-10-15 EA EA201200597A patent/EA029271B1/ru not_active IP Right Cessation
- 2010-10-15 SM SM20180628T patent/SMT201800628T1/it unknown
- 2010-10-15 BR BR112012008818-1A patent/BR112012008818B1/pt active IP Right Grant
- 2010-10-15 US US12/906,041 patent/US9611320B2/en active Active
- 2010-10-15 NZ NZ701709A patent/NZ701709A/en unknown
- 2010-10-15 DK DK10768878.0T patent/DK2488551T3/en active
- 2010-10-15 ES ES10768878.0T patent/ES2690943T3/es active Active
- 2010-10-15 CA CA2777691A patent/CA2777691C/en active Active
- 2010-10-15 AR ARP100103784A patent/AR078659A1/es active IP Right Grant
- 2010-10-15 AP AP2012006262A patent/AP2012006262A0/xx unknown
- 2010-10-15 ES ES18185172T patent/ES2973217T3/es active Active
- 2010-10-15 WO PCT/EP2010/006329 patent/WO2011045080A2/en active Application Filing
- 2010-10-15 SG SG10201704933PA patent/SG10201704933PA/en unknown
- 2010-10-15 PL PL18185172.6T patent/PL3421493T3/pl unknown
- 2010-10-15 UA UAA201205759A patent/UA106771C2/uk unknown
- 2010-10-15 NZ NZ599971A patent/NZ599971A/en unknown
- 2010-10-15 KR KR1020157017085A patent/KR101640520B1/ko active Active
- 2010-10-15 CN CN201080057237.3A patent/CN102791735B/zh active Active
- 2010-10-15 EP EP18185172.6A patent/EP3421493B1/en active Active
- 2010-10-15 EA EA201791876A patent/EA201791876A1/ru unknown
- 2010-10-15 GE GEAP201012707A patent/GEP201706604B/en unknown
- 2010-10-15 LT LTEP10768878.0T patent/LT2488551T/lt unknown
- 2010-10-15 TW TW099135321A patent/TWI537002B/zh active
- 2010-10-15 SI SI201031788T patent/SI2488551T1/sl unknown
- 2010-10-15 RS RS20181241A patent/RS57966B1/sr unknown
- 2010-10-15 PH PH1/2012/500711A patent/PH12012500711B1/en unknown
- 2010-10-15 KR KR1020127012677A patent/KR20120091221A/ko not_active Ceased
- 2010-10-15 CN CN201410752851.1A patent/CN104628857A/zh active Pending
2012
- 2012-04-03 IL IL219019A patent/IL219019B/en active IP Right Grant
- 2012-04-04 TN TNP2012000159A patent/TN2012000159A1/en unknown
- 2012-04-11 CL CL2012000914A patent/CL2012000914A1/es unknown
- 2012-04-12 ZA ZA2012/02642A patent/ZA201202642B/en unknown
- 2012-04-13 EC ECSP12011796 patent/ECSP12011796A/es unknown
- 2012-04-13 HN HN2012000708A patent/HN2012000708A/es unknown
- 2012-04-13 NI NI201200054A patent/NI201200054A/es unknown
- 2012-04-13 CR CR20120184A patent/CR20120184A/es unknown
- 2012-04-16 CU CUP2012000060A patent/CU24196B1/es active IP Right Grant
- 2012-04-16 GT GT201200114A patent/GT201200114A/es unknown
- 2012-05-11 MA MA34864A patent/MA33747B1/fr unknown
2013
- 2013-05-20 HK HK13105899.6A patent/HK1178183A1/zh unknown
2015
- 2015-03-04 JP JP2015042849A patent/JP6272793B2/ja active Active
2017
- 2017-03-06 US US15/451,280 patent/US10385126B2/en active Active
- 2017-03-06 US US15/451,253 patent/US10385124B2/en active Active
- 2017-03-06 US US15/451,275 patent/US10377821B2/en active Active
- 2017-03-06 US US15/451,268 patent/US10385125B2/en active Active
- 2017-06-21 JP JP2017121372A patent/JP2017212992A/ja active Pending
- 2017-08-15 IL IL254004A patent/IL254004B2/en unknown
2018
- 2018-10-11 HR HRP20181645TT patent/HRP20181645T1/hr unknown
- 2018-10-22 CY CY181101081T patent/CY1120913T1/el unknown
2019
- 2019-06-28 US US16/456,328 patent/US11299542B2/en active Active
2022
- 2022-03-07 US US17/687,909 patent/US20220195035A1/en active Pending

Also Published As

Publication number	Publication date
GT201200114A (es)	2014-08-11
EP3421493C0 (en)	2024-01-17
HN2012000708A (es)	2015-06-22
KR20150082672A (ko)	2015-07-15
TW201119675A (en)	2011-06-16
JP6272793B2 (ja)	2018-01-31
JP2017212992A (ja)	2017-12-07
GEP201706604B (en)	2017-01-25
JP5985987B2 (ja)	2016-09-06
US20170306012A1 (en)	2017-10-26
PT2488551T (pt)	2018-10-31
CN102791735A (zh)	2012-11-21
SMT201800628T1 (it)	2019-01-11
CU24196B1 (es)	2016-09-30
LT2488551T (lt)	2018-10-25
HK1178183A1 (zh)	2013-09-06
IL254004A0 (en)	2017-10-31
EP2488551B1 (en)	2018-07-25
US20200002413A1 (en)	2020-01-02
PH12012500711B1 (en)	2019-04-24
US10377821B2 (en)	2019-08-13
KR101640520B1 (ko)	2016-07-19
PL3421493T3 (pl)	2024-04-29
CY1120913T1 (el)	2019-12-11
AU2010306119A1 (en)	2012-05-03
EP2488551A2 (en)	2012-08-22
EA201791876A1 (ru)	2018-01-31
AR078659A1 (es)	2011-11-23
CN102791735B (zh)	2016-05-18
US10385126B2 (en)	2019-08-20
DK2488551T3 (en)	2018-10-08
NZ701709A (en)	2016-06-24
SG10201704933PA (en)	2017-07-28
CN104628857A (zh)	2015-05-20
ES2973217T3 (es)	2024-06-19
US20170306011A1 (en)	2017-10-26
CA2777691C (en)	2018-02-27
CU20120060A7 (es)	2013-04-19
AP2012006262A0 (en)	2012-06-30
ZA201202642B (en)	2013-06-26
PH12012500711A1 (en)	2012-11-12
EA201200597A1 (ru)	2012-12-28
WO2011045080A3 (en)	2011-07-07
ECSP12011796A (es)	2012-06-29
MX2012004400A (es)	2012-06-27
NZ599971A (en)	2014-12-24
EP3421493A1 (en)	2019-01-02
US20110117086A1 (en)	2011-05-19
MX351635B (es)	2017-10-23
CA2777691A1 (en)	2011-04-21
PL2488551T3 (pl)	2019-01-31
PE20121649A1 (es)	2012-12-08
WO2011045080A2 (en)	2011-04-21
IL219019B (en)	2019-05-30
MA33747B1 (fr)	2012-11-01
EA029271B1 (ru)	2018-03-30
SI2488551T1 (sl)	2019-01-31
UA106771C2 (uk)	2014-10-10
ES2690943T3 (es)	2018-11-23
EP3421493B1 (en)	2024-01-17
TWI537002B (zh)	2016-06-11
IL219019A0 (en)	2012-06-28
KR20120091221A (ko)	2012-08-17
BR112012008818B1 (pt)	2021-10-19
BR112012008818A2 (pt)	2018-05-22
JP2013507138A (ja)	2013-03-04
RS57966B1 (sr)	2019-01-31
US10385124B2 (en)	2019-08-20
US9611320B2 (en)	2017-04-04
HRP20181645T1 (hr)	2018-12-14
TN2012000159A1 (en)	2013-12-12
NI201200054A (es)	2012-08-20
CR20120184A (es)	2012-08-20
US10385125B2 (en)	2019-08-20
US20220195035A1 (en)	2022-06-23
JP2015145380A (ja)	2015-08-13
US11299542B2 (en)	2022-04-12
US20180022802A1 (en)	2018-01-25
US20170174761A1 (en)	2017-06-22
IL254004B2 (en)	2023-06-01
CL2012000914A1 (es)	2012-09-14

Publication	Publication Date	Title
IN2012DN03348A (ro)	2015-10-23
MX2020010639A (es)	2020-10-28	Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
JO3097B1 (ar)	2017-03-15	الأجسام المضادة c-Met
NZ599737A (en)	2015-02-27	Il-17a antagonists
PH12014502419A1 (en)	2017-06-05	Specific binding proteins and uses thereof
MX2019004193A (es)	2019-08-05	Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
WO2009126934A3 (en)	2009-12-30	Detection and tratment of pancreatic, ovarian and other cancers
WO2010017515A3 (en)	2010-04-01	Breast cancer specific markers and methods of use
PH12014501164A1 (en)	2014-10-20	Anti-cd98 antibodies and methods of use thereof
MX2012001782A (es)	2012-04-19	Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina.
NZ584787A (en)	2012-12-21	Inhibition of angiogenesis with a Bv8 antagonist
MX352373B (es)	2017-11-22	Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno.
MX347463B (es)	2017-04-26	Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf.
WO2013149219A3 (en)	2013-11-21	Fully human antibodies that bind to vegfr2
MX362497B (es)	2019-01-21	Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
TH133902A (th)	2014-05-26	มอนอโคลนัลแอนติบอดีสำหรับโพรแกสตรินและการใช้ประโยชน์ของมอนอโคลนัลแอนติบอดี
TR201905240T4 (tr)	2019-05-21	LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı.
UA104739C2 (en)	2014-03-11	c-MET ANTIBODIES